Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy

  • Jeter A
  • Kang Y
N/ACitations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation. However, occasionally bortezomib-induced neuropathy can be severe and affects motor and/or autonomic nerves, and may be mediated by immune process. The role of immune modulation therapy in the management of bortezomib-induced PN was not well established. Here, we reported a case of bortezomib-induced severe PN that responded well to plasma exchange and steroid treatment.

Cite

CITATION STYLE

APA

Jeter, A., & Kang, Y. (2012). Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy. Experimental Hematology & Oncology, 1(1). https://doi.org/10.1186/2162-3619-1-20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free